Abstract: The present invention concerns pharmaceutical compositions containing metformin as an active substance and a hydrocolloid-forming agent as a retardant and optionally standard pharmaceutical auxiliary substances, the residual moisture content in the pharmaceutical composition being 0.5-3% by weight. The invention also concerns a process for producing pharmaceutical compositions containing metformin as an active substance and a hydrocolloid-forming agent as a retardant and optionally standard pharmaceutical auxiliary substances characterized in that the active substance and retarding agent or a portion thereof are granulated with an aqueous solvent which can optionally contain a binder and where appropriate the other portion of the retardant or other standard pharmaceutical auxiliaries are admixed with the granulate which is then dried until the residual moisture content is reduced to 0.5-3% by weight.
Type:
Grant
Filed:
March 14, 1997
Date of Patent:
September 21, 1999
Inventors:
Jorn Moeckel, Rolf-Dieter Gabel, Heinrich Woog
Abstract: A capsule dosage form containing solid form of terazosin in a solid carrier is disclosed. The capsule dosage form is stable under accelerated stability conditions and therapeutically equivalent to known liquid-filled terazosin capsules.
Type:
Grant
Filed:
August 1, 1996
Date of Patent:
September 14, 1999
Assignee:
Novartis Corporation
Inventors:
Jeffrey W. Guentensberger, Christopher L. Pelloni
Abstract: An oral solid dosage form, comprising a compressed tablet including an excipient comprising (a) microcrystalline cellulose; and (b) a compressibility augmenting agent which (I) physically restricts the proximity of the interface between adjacent cellulose surfaces (e.g., silicon dioxide); or (ii) inhibits interactions between adjacent cellulose surfaces (e.g., sodium lauryl sulfate); or (iii) accomplishes both (i) and (ii) above; together with an active agent, is disclosed which provides improved disintegration and/or absorptivity to the oral solid dosage form when orally administered to human patients. The excipient comprises agglomerated particles of said microcrystalline cellulose and said compressibility augmenting agent in intimate association with each other.
Type:
Grant
Filed:
June 4, 1997
Date of Patent:
September 7, 1999
Assignee:
Edward Mendell Co., Inc.
Inventors:
John N. Staniforth, Bob E. Sherwood, Edward A. Hunter
Abstract: The invention relates to sustained release formulations comprising 11-?4-?2-(2-hydroxyethoxy)ethyl!-1-piperazinyl!dibenzo?b,f! ?1,4!thiazepine or a pharmaceutically acceptable salt thereof, to methods of treating psychotic states and hyperactivity utilizing the sustained release formulations and to a process for preparing the sustained release formulations.
Type:
Grant
Filed:
May 28, 1997
Date of Patent:
September 7, 1999
Assignee:
Zeneca Limited
Inventors:
Bhavnish Vinod Parikh, Robert Joseph Timko, William Joseph Addicks
Abstract: A continuous process for producing microspheres wherein small particle sizes can be obtained without the problem of foaming. A drug and polymer containing dispersed phase is continuously introduced into a high intensity emulsification vessel along with a continuous phase. An emulsion of the dispersed phase is formed in the continuous phase by high intensity mixing effective to quickly solidify the dispersed phase polymer without having to take steps to address foaming.
Type:
Grant
Filed:
February 13, 1997
Date of Patent:
August 31, 1999
Assignee:
Oakwood Laboratories L.L.C.
Inventors:
Bagavathikanun Chithambara Thanoo, James Murtagh
Abstract: Solid drug forms obtainable by extrusion of a melt comprising, besides one or more active substances, a mixture of homo- and/or copolymers of N-vinylpyrrolidone and degraded starches.
Type:
Grant
Filed:
September 16, 1997
Date of Patent:
August 31, 1999
Assignee:
BASF Aktiengesellschaft
Inventors:
Jorg Breitenbach, Jens Rieger, Joerg Rosenberg, Axel Sanner
Abstract: A powdery pharmaceutical composition comprising nicotine or a derivative thereof and starch microspheres. The starch microspheres are preferably degradable epichlorhydrin cross-linked starch microspheres. The average diameter of the microspheres is from around 1 .mu.m to around 200 .mu.m, preferably around 45 .mu.m. The invention also encompasses a method for manufacturing a powdery pharmaceutical composition comprising nicotine and starch microspheres. The invention further comprises a method of diminishing the desire of a subject to use tobacco which comprises the step of administering to the subject the above powdery pharmaceutical composition.
Abstract: The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epichelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.
Type:
Grant
Filed:
March 12, 1997
Date of Patent:
August 10, 1999
Assignee:
The Procter & Gamble Company
Inventors:
Richard John Dansereau, Russell Youker Mosher, Douglas Wayne Axelrod, William Kendall Sietsema
Abstract: A percutaneously administrable base composition which facilitates the percutaneous absorption of drugs and is remarkably reduced in the irritancy against the skin. The composition comprises 10-60 wt. % of lower alcohol, 10-50 wt. % of humectant, 10-70 wt. % of water, 0.1-15 wt. % of abirritant and 0.1-15 wt. % of absorption promoter. A drug composition is prepared by adding to the above composition various active ingredients such as antitussive, expectorant, skeletal muscle relaxant, antivertiginous drug, narcotic, drug for the circulatory system, and so forth.
Abstract: Disclosed are budesonide pellets with a controlled release pattern containing, from the inside to the outside: a) neutral pellets; b) an active principle layer of micronized budesonide and one or more water-soluble auxiliaries; c) a first lacquer coating consisting of 80 to 97% of at least one lacquer insoluble in gastric fluids but soluble in intestinal fluids and 3 to 20% of at least one lacquer insoluble in both gastric and intestinal fluids; and d) a second lacquer coating consisting of at least one lacquer insoluble in gastric and intestinal fluids. The invention also relates to a process for producing budesonide pellets with a controlled release pattern.
Type:
Grant
Filed:
July 15, 1996
Date of Patent:
August 3, 1999
Assignee:
Dr. Falk Pharma GmbH
Inventors:
Peter Gruber, Hans Joachim Lach, Norbert Otterbeck
Abstract: A method for enhancing a stable concentration of cellular creatine in a human includes dissolving an effervescent containing an acidic edible salt form of creatine in water. Once the mixture has completely dissolved the solution is immediately ingested, and an effective amount of creatine is absorbed. Preferably, the effervescent is in the form of a tablet which contains creatine in the form of an edible salt, a mixture of acids, and sodium.
Abstract: The present invention relates to expanded solid compositions whose matrix comprises a cellular network formed from a starch-rich product and contains at least some expanded thermoplastic hollow particles of polymer or copolymer of an ethylenically unsaturated monomer or mixture of such monomers. These compositions constitute new dosage forms for cosmetic or dermatological use. These compositions either take the form of expanded cylinders, pellets, leaves or flakes, or the form of powder. When reduced to the powder state, they may also be used as a make-up or hygiene composition to be rehydrated or to be used as such.
Type:
Grant
Filed:
May 29, 1996
Date of Patent:
July 20, 1999
Assignee:
L'Oreal
Inventors:
Veronique Roulier, Myriam Mellul, Gerard Gabin, Katrin Holz
Abstract: The present invention relates to a sustained release formulation used for treatment or prevention of the diseases, which contains a therapeutically effective substance as an active ingredient, collagen as a drug carrier, and glycosaminoglycan as an additive. The formulation allows controlled release of the therapeutically effective substance.
Abstract: A controlled release dosage form which comprises:(a) a homogeneous compressed core which comprises a compressed granulation of:(i) particles of a calcium channel blocker compound coated with an enteric polymer that are dispersed onto a solid pharmaceutical filler; and(b) a continuous compressed outer layer around said homogeneous compressed core which comprises a compressed granulation of:(i) one or more pharmaceutically acceptable polymers which form a hydrogel in which calcium channel blocker compound is dispersed.
Abstract: Submicron size particles of pharmaceutical or other water-insoluble or poorly water-insoluble substances are prepared using a combination of one or more surface modifiers/surfactants such as polaxomers, poloxamines, polyoxyethylene sorbitan fatty acid esters and the like together with natural or synthetic phospholipids. Particles so produced have a volume weighted mean particle size at least one-half smaller than obtainable using a phospholipid alone. Compositions so prepared are resistant to particle size growth on storage.
Abstract: The invention provides an agglomerate composition composed of units of aggregated fine particles and methods for its manufacture and use. The agglomerate composition units are composed of fine particles having a mean particle size in the range of 1 .mu.m to 5 .mu.m, and usually includes a medicament powder. The agglomerate units have a mean size in the range from 200 .mu.m to 500 .mu.m and have a friability index in the range from about 10 to 60.
Type:
Grant
Filed:
May 9, 1997
Date of Patent:
July 13, 1999
Assignee:
Inhale Therapeutic Systems
Inventors:
Keith A. Johnson, Marc S. Gordon, Shirley W. Lyons
Abstract: A substantially flexible, dry matrix with antimicrobial properties is made from a matrix comprising natural or synthetic, woven, non-woven or knitted fibers, said matrix having been uniformly coated with an amount of a non-aqueous treatment solution sufficient to allow said matrix to retain its substantially dry characteristics. In a preferred embodiment, said non-aqueous treatment solution has between about 70% and 99% of at least one glycol compound, between about 1% and 15% of a PVP-iodine and optionally between about 0 and 15% of a non-ionic surfactant.Also, skin is treated to prevent disease, such as the disinfecting of teats on dairy cows during milking, by wiping the skin with the article.
Abstract: A liquid oil and fat ingredient or others are carried by pores of a porous carrier composed of porous starch grain obtained by reacting an enzyme having raw starch digestive activity onto the starch. With starch being used as porous carrier, the powder preparation according to the present invention is not harmful to the human body, it can be supplied continuously in great volumes, manufactured cheaply without difficult processing, and moreover, being completely biodegradable, this powder preparation does not cause any environmental problems. It can be used in various industrial fields.
Abstract: The present invention relates to nanoparticles, and in particular nanocapsules, provided with a lamellar coating obtained from a silicone surfactant, and to their use in a composition, in particular a topical composition, for treatment of the skin, mucosae, nails, scalp and/or hair.